Emyria provides unique combination of drug development and therapy delivery
–News Direct– Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive after announcing the company has received strong support for its recent placement, securing firm commitments from new and sophisticated investors to raise $2 million (before costs). Alongside the oversubscribed placement, Emyria is also undertaking